Angtiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) will release the third quarter earnings for 2009 on Monday, November 9. The company will hold a conference call at 11:00 am ET that day to discuss the financial results. Interested parties may access the call by dialing 800.599.9829 or 617.847.8703 for callers outside of North America. The pass code for the call is 64385781. A webcast of the presentation will be available on the company’s Investors site, www.angiotech.com/investors, on the Events & Webcasts page.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter.
Angiotech Pharmaceuticals, Inc. (Angiotech), is a specialty pharmaceutical and medical device company that discovers, develops and markets technologies primarily focused on acute and surgical applications. The Company generates its revenue through the sales of medical products and components, as well as from royalties derived from sales by its partners of products utilizing certain of its own technologies. The Company operates in two segments: Pharmaceutical Technologies and Medical Products. The Pharmaceuticals Technologies segment includes royalty revenue generated from licensing its paclitaxel technology to various partners. The Medical Products segment manufactures and markets a range of single use, specialty medical devices. The Medical Products segment also manufactures finished medical devices and medical device components for third party medical device manufacturers and marketers.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
